AC105 in Patients With Acute Traumatic Spinal Cord Injury
Status:
Terminated
Trial end date:
2015-05-01
Target enrollment:
Participant gender:
Summary
The principal aim of this study was to establish the feasibility of rapid administration,
safety, and tolerability of AC105 in patients with acute spinal cord injury.
Phase:
Phase 2
Details
Lead Sponsor:
Acorda Therapeutics
Collaborators:
DP Clinical, Inc. United States Department of Defense